Hypericin, the active component of St. John's wort, inhibits glutamate release in the rat cerebrocortical synaptosomes via a mitogen-activated protein kinase-dependent pathway

European Journal of Pharmacology

Volumn 634, Issue 1-3, 2010, Pages 53-61

  Chang, Yi ^a,c   Wang, Su Jane ^b  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b The Graduate Institute of Basic Medicine   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cerebrocortical synaptosome; Depression; Glutamate exocytosis; Hypericin; Mitogen activated protein kinase

Indexed keywords

4 AMINOPYRIDINE; CALCIUM CHANNEL; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; GLUTAMIC ACID; HYPERICIN; MITOGEN ACTIVATED PROTEIN KINASE; VOLTAGE DEPENDENT ANION CHANNEL; PERYLENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN SYNAPTOSOME; CALCIUM TRANSPORT; CHELATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; ENZYME REPRESSION; EXOCYTOSIS; MALE; MEMBRANE POTENTIAL; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; HYPERICUM; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; SYNAPTOSOME;

ANIMALS; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMIC ACID; HYPERICUM; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; PERYLENE; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTOSOMES;

EID: 77951209179     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.035     Document Type: Article

References (43)

1. Adell A., Castro E., Celada P., Bortolozzi A., Pazos A., Artigas F. Strategies for producing faster acting antidepressants. Drug Discov. Today 2005, 10:578-585.
2. 2(5). J. Neurochem. 1987, 48:552-559.
3. Attwell D., Barbour B., Szatkowski M. Nonvesicular release of neurotransmitter. Neuron 1993, 11:401-407.
4. Baldwin M.L., Rostas J.A., Sim A.T. Two models of exocytosis from synaptosomes are differentially regulated by protein phosphatase types 2A and 2B. J. Neurochem. 2003, 85:1190-1199.
5. Barrie A.P., Nicholls D.G., Sanchez-Prieto J., Sihra T.S. An ion channel locus for the protein kinase C potentiation of transmitter glutamate release from guinea pig cerebrocortical synaptosomes. J. Neurochem. 1991, 57:1398-13404.
6. Beaubrun G., Gray G.E. A review of herbal medicines for psychiatric disorders. Psychiatr. Serv. 2000, 51:1130-1134.
7. Bonanno G., Giambelli R., Raiter L., Tiraboschi E., Zappettini S., Musazzi L., et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J. Neurosci. 2005, 25:3270-3279.
8. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
9. Cavelier P., Attwell D. Neurotransmitter depletion by bafilomycin is promoted by vesicle turnover. Neurosci. Lett. 2007, 412:95-100.
10. Duman C.H., Schlesinger L., Kodama M., Russell D.S., Duman R.S. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol. Psychiatry 2007, 61:661-670.
11. Dunkley P.R., Jarvie P.E., Heath J.W., Kidd G.J., Rostas J.A. A rapid method for isolation of synaptosomes on Percoll gradients. Brain Res. 1986, 372:115-129.
12. Dunlop J. Glutamate-based therapeutic approaches: targeting the glutamate transport system. Curr. Opin. Pharmacol. 2006, 6:103-107.
13. Fugh-Berman A., Cott J.M. Dietary supplements and natural products as psychotherapeutic agents. Psychosom. Med. 1999, 61:712-728.
14. Greengard P., Valtorta F., Czernik A.J., Benfenati F. Synaptic vesicle phosphoproteins and regulation of synaptic function. Science 1993, 259:780-785.
15. Grewal S., York R., Stork P. Extracellular-signal-regulated kinase signaling in neurons. Curr. Opin. Neurobiol. 1999, 9:544-553.
16. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985, 260:3440-3450.
17. Jovanovic J.N., Benfenati F., Siow Y.L., Sihra T.S., Sanghera J.S., Pelech S.L. Neurotrophins stimulate phosphorylation of synapsin I by MAP kinase and regulate synapsin I-actin interactions. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:3679-3683.
18. Jovanovic J.N., Czernik A.J., Fienberg A.A., Greengard P., Sihra T.S. Synapsins as mediators of BDNF-enhanced neurotransmitter release. Nat. Neurosci. 2000, 3:323-329.
19. Kendell S.F., Krystal J.H., Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin. Ther. Targets 2005, 9:153-168.
20. McMahon H.T., Nicholls D.G. The bioenergetics of neurotransmitter release. Biochim. Biophys. Acta 1991, 1059:243-264.
21. Michael-Titus A.T., Bains S., Jeetle J., Whelpton R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex: a possible mechanism of neuroprotection in major depression. Neuroscience 2000, 100:681-684.
22. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 2006, 110:135-370.
23. Millan C., Sanchez-Prieto J. Differential coupling of N and P/Q-type calcium channels to glutamate exocytosis in the rat cerebral cortex. Neurosci. Lett. 2002, 330:29-32.
24. Muller W.E. Current St. John's wort research from mode of action to clinical efficacy. Pharmacol. Res. 2003, 47:101-109.
25. Muller W.E., Rolli M., Schafer C., Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997, 30:102-107.
26. Neary J.T., Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res. 1999, 816:358-363.
27. Nicholls D.G. The glutamatergic nerve terminal. Eur. J. Biochem. 1993, 212:613-631.
28. Nicholls D.G. Presynaptic modulation of glutamate release. Prog. Brain Res. 1998, 116:15-22.
29. Nicholls D.G., Sihra T.S., Sanchez-Prieto J. Calcium-dependent and -independent release of glutamate from synaptosomes monitored by continuous fluorometry. J. Neurochem. 1987, 49:50-57.
30. Paul I.A., Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann. N. Y. Acad. Sci. 2003, 100:250-272.
31. Pereira D.B., Carvalho A.P., Duarte C.B. Non-specific effects of the MEK inhibitors PD98059 and U0126 on glutamate release from hippocampal synaptosomes. Neuropharmacology 2002, 42:9-19.
32. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., et al. Subtype-specific alterations of γ-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 2004, 61:705-713.
33. Sapolsky R.M. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol. Psychiatry 2000, 48:755-765.
34. Schechter L.E., Ring R.H., Beyer C.E., Hughes Z.A., Khawaja X., Malberg J.E., Rosenzweig-Lipson S. Innovative approaches for the development of antidepressant drugs: current and future strategies. J. Am. Soc. Exp. Neurother. 2005, 2:590-611.
35. Schenk U., Menna E., Kim T., Passafaro M., Chang S., Camilli P.D. A novel pathway for presynaptic mitogen-activated kinase activation via AMPA receptors. J. Neurosci. 2005, 25:1654-1663.
36. 2+ entry preferentially effects protein dephosphorylation, phosphorylation, and glutamate release. J. Biol. Chem. 1992, 267:1983-1989.
37. Skolnick P. Antidepressants for the new millennium. Eur. J. Pharmacol. 1999, 375:31-40.
38. Skolnick P. Modulation of glutamate receptors: strategies for the development of novel antidepressants. Amino Acids 2002, 23:153-159.
39. 2+ and glutamate release. J. Neurochem. 1989, 53:1693-1699.
40. 2+ entry in rat cerebrocortical nerve terminals (synaptosomes). J. Pharmacol. Exp. Ther. 2004, 309:951-958.
41. 2+ channels. Synapse 2003, 48:170-177.
42. Yamagata Y., Jovanovic J.N., Czernik A.J., Greengard P., Obata K. Bidirectional changes in synapsin I phosphorylation at MAP kinase-dependent sites by acute neuronal excitation in vivo. J. Neurochem. 2002, 80:835-842.
43. Zarate C.A., Quiroz J., Payne J., Manji H.K. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol. Bull. 2002, 36:35-83.